Inactive Instrument

Grifols SA Stock BME

Equities

ES0171996012

Pharmaceuticals

End-of-day quote BME
- EUR - Intraday chart for Grifols SA
Sales 2024 * 7.09B 7.53B Sales 2025 * 7.63B 8.1B Capitalization 5.22B 5.54B
Net income 2024 * 489M 519M Net income 2025 * 732M 777M EV / Sales 2024 * 2.02 x
Net Debt 2024 * 9.12B 9.68B Net Debt 2025 * 8.33B 8.85B EV / Sales 2025 * 1.78 x
P/E ratio 2024 *
11 x
P/E ratio 2025 *
7.74 x
Employees -
Yield 2024 *
-
Yield 2025 *
2.77%
Free-Float 89.28%
More Fundamentals * Assessed data
Managers TitleAgeSince
Chief Executive Officer 55 Feb. 05
Director of Finance/CFO 67 06-12-31
Chairman 65 06-04-04
Members of the board TitleAgeSince
Chairman 65 06-04-04
Director/Board Member 68 00-04-12
Director/Board Member 61 01-07-26
More insiders
Grifols, S.A. specializes in the research, development, manufacturing and marketing of therapeutic products and medical devices for use in hospitals and medical analysis laboratories. Net sales break down by family of products and services as follows: - products derived from plasma (84.3%): products for use by the pharmaceutical and biotechnology industries; - diagnostic machines and reagents (10.2%): in vitro hemophilic diagnostic equipment, coagulation analyzers, infectious serology reagents, etc. for use primarily by blood banks and transfusion centers; - hospital products (2.4%): non-biological surgical products, radiology and nutritional products, etc. for use by hospital pharmacies; - other (3.1%): primarily intermediate biological products and subcontracted manufacturing services. Net sales are distributed geographically as follows: Spain (5.5%), European Union (13.6%), the United States and Canada (59.1%) and other (21.8%).
Calendar
More about the company